WO2002083174A1 - Procede d'administration d'une substance dans le ventricule gauche - Google Patents

Procede d'administration d'une substance dans le ventricule gauche Download PDF

Info

Publication number
WO2002083174A1
WO2002083174A1 PCT/JP2002/003534 JP0203534W WO02083174A1 WO 2002083174 A1 WO2002083174 A1 WO 2002083174A1 JP 0203534 W JP0203534 W JP 0203534W WO 02083174 A1 WO02083174 A1 WO 02083174A1
Authority
WO
WIPO (PCT)
Prior art keywords
left ventricle
substance
administering
administering substance
function
Prior art date
Application number
PCT/JP2002/003534
Other languages
English (en)
Japanese (ja)
Inventor
Atsushi Nishimura
Nobuyuki Koyama
Toshifumi Watanabe
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of WO2002083174A1 publication Critical patent/WO2002083174A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'administration d'une substance dans le ventricule gauche du coeur d'un mammifère non humain peut être réalisée de manière pratique et efficace lorsqu'elle est associée à une réduction sensible de l'aorte de ce mammifère. Ce procédé d'administration peut donc être utilisé dans la clarification d'une fonction inconnue d'un gène, dans le criblage d'un composé candidat de médicament, dans l'évaluation des effets d'un médicament etc.
PCT/JP2002/003534 2001-04-10 2002-04-09 Procede d'administration d'une substance dans le ventricule gauche WO2002083174A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-110990 2001-04-10
JP2001110990 2001-04-10
JP2002009142 2002-01-17
JP2002-009142 2002-01-17

Publications (1)

Publication Number Publication Date
WO2002083174A1 true WO2002083174A1 (fr) 2002-10-24

Family

ID=26613345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/003534 WO2002083174A1 (fr) 2001-04-10 2002-04-09 Procede d'administration d'une substance dans le ventricule gauche

Country Status (1)

Country Link
WO (1) WO2002083174A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0970289A (ja) * 1995-06-27 1997-03-18 Takeda Chem Ind Ltd ヒトｃｒｆ２レセプター蛋白質、その製造法および用途
WO1999046277A1 (fr) * 1998-03-09 1999-09-16 Smithkline Beecham Corporation POLYNUCLEOTIDES ET POLYPEPTIDES D'EDG-1c HUMAIN ET LEURS PROCEDES D'UTILISATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0970289A (ja) * 1995-06-27 1997-03-18 Takeda Chem Ind Ltd ヒトｃｒｆ２レセプター蛋白質、その製造法および用途
WO1999046277A1 (fr) * 1998-03-09 1999-09-16 Smithkline Beecham Corporation POLYNUCLEOTIDES ET POLYPEPTIDES D'EDG-1c HUMAIN ET LEURS PROCEDES D'UTILISATION

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
HARADA K. ET AL.: "Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction", CIRCULATION, vol. 100, 1999, pages 2093 - 2099, XP002952983 *
JEYASEELAN R. ET AL.: "A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes", J. BIOL. CHEM., vol. 272, no. 36, 1997, pages 22800 - 22808, XP002952981 *
KUWAHARA K. ET AL.: "Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro", CIRCULATION, vol. 100, 1999, pages 1116 - 1124, XP002952980 *
MCVEY M.J. ET AL.: "Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: Coronary hemodynamic and cardioprotective effects in the canine myocardium", J. CARDIOVASC. PHARMACOL., vol. 33, no. 5, 1999, pages 703 - 710, XP002952984 *
MIYAMOTO M.I. ET AL.: "Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 2, 2000, pages 793 - 798, XP002952979 *
MOCHIZUKI S. ET AL.: "Na+/Ca++ exchanger and myocardial ischemia/reperfusion", JPN. HEART J., vol. 39, 1998, pages 707 - 714, XP002952985 *
SHINMURA K. ET AL.: "Catheter-delivered in vivo gene transfer into rat myocardium using the fusigenic liposomal mediated method", JPN. HEART J., vol. 41, 2000, pages 633 - 647, XP002952978 *
ZOU Y. ET AL.: "CARP, a cardiac ankyrin repeat protein, is downstream in the Nkx2-5 homeobox gene pathway", DEVELOPMENT, vol. 124, 1997, pages 793 - 804, XP002952982 *

Similar Documents

Publication Publication Date Title
CN102302493B (zh) 活化祖细胞/干细胞的方法
LU92611I2 (fr) Sitagliptin et ses dérivés pharmaceutiquement acceptables (JANUVIA)
ATE442851T1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
WO2005012485A3 (fr) Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
Ahmad et al. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third‐degree burn injury
GB2427873A (en) Method for making high purity cardiomyocyte preparations suitable for regenerative medicine
WO2002015920A3 (fr) Traitement des maladies d'hyperproliferation
WO2002055721A3 (fr) Systemes de transfection modulaires
RU2769446C1 (ru) Применение чиглитазара и родственных ему соединений
Fuchs et al. The stimulation of dopa decarboxylase activity by ecdysone and its enhancement by cyclic AMP in adult mosquitoes
WO2002083174A1 (fr) Procede d'administration d'une substance dans le ventricule gauche
Rentsch Genesis of Heinz bodies and methemoglobin formation
Dzemeshkevich et al. Plasmapheresis in the treatment of posttransplant cardiomyopathy
Wang et al. Advanced donor age impairs bone marrow cell therapeutic efficacy for cardiac disease
AU2003302499A1 (en) Methods for antigen masking of red blood cells resulting in reduced hemolysis
US7423009B2 (en) Method for treatment of kidney diseases
WO2001048164A3 (fr) Therapie genique destinee a une insuffisance cardiaque congestive
Zhu et al. Exchange proteins directly activated by cAMP mediate cardiac repolarization and arrhythmogenesis during chronic heart failure
Cornford et al. Schistosoma mansoni, S. japonicum, S. haematobium: Glycogen content and glucose uptake in parasites from fasted and control hosts
Yorgey et al. Evaluation of drug absorption and presystemic metabolism using an in situ intestinal preparation
Matijatko et al. Serum cor tisol and insulin concentrations in dogs naturally infected Serum cor tisol and insulin concentrations in dogs naturally infected with Babesia canis
Mills et al. Arthritis and primary biliary cirrhosis.
CN101327221A (zh) 麦冬皂苷d作为组织因子途径抑制剂的医药用途
Sica et al. Disposition and safety of omapatrilat in subjects with renal impairment
RU2002116408A (ru) Способ реперфузионной терапии больных острым инфарктом миокарда

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP